Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 20, Issue 3, 1999, Pages 290-294

  Van Roon, E N ^a   Verzijl, J M ^a   Juttmann, J R ^b   Lenderink, A W ^a   Blans, M J ^b   Egberts, A C G ^a,c  

^a GGZ Midden Brabant   (Netherlands)

^b CPRLab   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Antiretroviral therapy; CD4; Determinants; Discontinuation; Epidemiology; HAART; Stopping therapy; Surveillance; Swit ching therapy; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INDINAVIR; RITONAVIR; SAQUINAVIR;

ADULT; AGED; ANEMIA; ARTICLE; DRUG WITHDRAWAL; FEMALE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOMES RESEARCH; PATIENT MONITORING; PRIORITY JOURNAL; VIRUS LOAD; VOMITING;

HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 0032928150     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199903010-00012     Document Type: Article

References (15)

1. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ 1997;1315:1194-9.
2. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
3. Hammer SM, Squifies KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
4. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996;334:1011-7.
5. Villalba N, Gomez-Cano M, Casas E, Casas E, Soriano V, valencia E, Gonzalez-Lahoz J. Safety and efficacy of two different triple drug combinations in which either lamivudine or didanosine were administered with stavudine plus indinavir. AIDS 1997;11:1896-7.
6. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996;2:760-6.
7. Kohl NE, Emini EA, Schleif WA, et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 1988;85:4686-90.
8. Burger DM, Hoetelmans RMW, Koopmans PP, et al. Clinically relevant drug interactions with antiretroviral agents. Antiviral Ther 1997;2:149-65.
9. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA 1997;277: 1962-9.
10. Gazzard BG, Moyle GJ, Weber J, et al. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997;349:1086-92.
11. Japour AJ, Chatis PA, Eigenrauch HA, et al. Detection of human immunodeficiency virus type I clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA-RNA hybridization. Proc Natl Acad Sci USA 1991;88:3092-6.
12. Mayers DL, Japour AJ, Arduino J-M, et al. Dideoxynucleoside resistance emerges with prolonged zidovudine therapy. Antimicrob Agents Chemother 1994;38:307-14.
13. Condra JH, Schlief WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995;374:569-71.
14. Roberts NA, Craig JC, Sheldon J. Resistance and cross-resistance with saquinavir and other HIV-protease inhibitors: theory and practice. AIDS 1998;12:453-60.
15. Casado JL, Perez-Elias MJ, Antela A, et al. Risk factors for ritonavir intolerance and outcome after change to indinavir. AIDS 1998;12:335-6.